SignalCorporate
Eton outlines more than $175M 2026 revenue guidance as it targets an April 2027 LIBERVANT launch
Eton targets $175M+ 2026 revenue with April 2027 LIBERVANT launch.
Context
What happened: Eton Pharmaceuticals outlined 2026 revenue guidance of more than $175M and said it targets an April 2027 launch of LIBERVANT.
Key numbers: Q3 2026 revenue $57.9 million, up 158% year over year. 2026 revenue guidance above $175M. LIBERVANT launch targeted for April 2027.
Why it matters: Management described the quarter as one with record revenue, significant margin expansion and strong cash flow generation, alongside the forward guidance and launch timeline.
What changed
Eton Pharmaceuticals outlined 2026 revenue guidance of more than $175M and said it targets an April 2027 launch of LIBERVANT.
Why it matters
Management described the quarter as one with record revenue, significant margin expansion and strong cash flow generation, alongside the forward guidance and launch timeline.